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Sunday, February 8, 2015 111apotency remain unexplained. We sought to determine the relevance of ICaLin
arrhythmogenic effects of one quinolone antibiotic, sparfloxacin (SPX).
Methods andResults: In thepresent study,we investigated possible involvement
of ICaL in the SPX-induced APD prolongation in neonatal rat ventricular myo-
cytes using patch clamp technique. In the presence of IKr blocker, E4031, APD
prolongation was evident perfused with sparfloxacin at 3  104 M and stimu-
lated at 2 Hz, indicating the involvement of additional channel in SPX-induced
proarrhythmic properties. The APD prolongation was associated with a slowing
of inactivation of ICaL. In contrast to SPX, four other quinolones including cipro-
floxacin, enoxacin, ofloxacin, and levofloxacin, which are not related to VT, did
not affect ICaL. Sparfloxacin increased the inactivation time constants of ICaL in a
concentration-dependent manner, resulting larger steady-state currents. Further
analysis showed that sparfloxacin reduced Ca2þ-dependent component of
steady-state inactivation. Consistent with modulation of Ca2þ-dependent inacti-
vation (CDI) by sparfloxacin, replacement of extracellular Ca2þwith Ba2þ abol-
ished sparfloxacin action on ICaL inactivation. Use-dependency wasmeasured by
applying repetitive voltage pulses at 2 Hz.We found that sparfloxacinmodulated
Ca2þ-dependent inactivation of ICaL in a use-dependent way.
Conclusion: The present findings demonstrate the role of ICaLin SPX-induced
APD prolongation. We further provide the evidence that SPX modified the
shape of ICaL by altering kinetics of Ca
2þ-dependent inactivation (APD).
This study suggests that quinolones causing delay of ICaL inactivation com-
bined with IKr block may have more adverse effects than those with purely se-
lective IKr block.
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Lethal arrhythmia is one of themajor safety concerns for developing drug candi-
date compounds, nevertheless, conventional cardiotoxicity prediction methods
like in vitro hERG/APD and in vivo QT assay cannot be eliminated the false
negative/positive problem. To overcome this problem, we have developed an
on-chip new in vitro predictive cardiotoxicity assay having a quality of clinical
screening using constructive human cardiomyocyte networks derived from hu-
man stem cells (hES-CMs) employing a spatiotemporal measurement of fluctu-
ation (short-termvariability; STV) of temporal repolarization of cells and spatial
cell-to-cell conduction, representing two origins of lethal arrhythmia. First, we
examined the electrophysiological prolongation of field potential durations
(FPDs) of human cardiomyocytes to compare the conventional in vivo QT pro-
longation and clinical results. The results showed (1) FPD prolongation has the
ability to detect QT/pro-arrhythmic risks almost similar to the conventional
in vitro APD measurements such as papillary muscle and Langendorff hearts.
However, they did not show significant improvement of the false-positive/
negative problems. Then we evaluated the new two spatiotemporal fluctuations,
and found that (2) temporal fluctuations of FPDs (STVFPD) predicted ventricular
arrhythmia risks more precisely in most of the representative compounds
including false-positive/negative compounds except for terfenadine, and that
(3) even the risk of those false-negative drugs including terfenadine was pre-
dicted by the fluctuation of spatial cell-to-cell conduction in the lined-up cardi-
omyocyte network. In conclusion, only the replacement of animal cells to human
cardiomyocytes in conventional in vitro screening is not enough to get precise
prediction, whereas, the combination of human cardiomyocytes with the new
approach of two spatiotemporal fluctuation measurements of temporal STVFPD
and spatial STVConductance gives us an potential of global precise predictive
arrhythmic cardiotoxicity as a quasi-in vivo human cell network screening
beyond conventional hERG and APD/QT assays.
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A new trend in the industry utilizes induced pluripotent stem cells (iPSCs) for
functional assays to identify cardiac pathologies and their genetic underpin-
nings (such as Long QT Syndrome (LQTS)), in addition to cardiotoxicity
profiling of pharmaceutical compounds.
The here utilized CardioExcyte 96 system is a hybrid instrument that com-
bines impedance readout (a correlate of cell contractility) with electric field po-
tential recordings of the compound signal that is generated by cellular action
potentials. These electrophysiological measurements are label-free and allowinvestigations in High Throughput format. In addition, the instrument is
capable of electrical stimulation of the cellular monolayer, while the rapid
acquisition rate of 1ms allows a more accurate description of signal features
and nuances stemming from pharmacological effects. A dedicated software
package for rapid data handling and real-time analysis is based on novel algo-
rithms that allow a comprehensive investigation of the cellular beat signal.
A broad range of cell lines was successfully validated, such as stem cell-derived
cardiomyocytes from Axiogenesis (human: Cor4U, murine: CorAt), GE
Healthcare (Cytiva), Cellectis (human, 3D-clusters: hES-CMC) and CDI
(iCell). Furthermore, the pharmacological effects of a number of reference
compounds on these cell typeswere evaluated and their phenotype correctly iden-
tified. For example, the effects of compounds like Blebbistatin, which blocks
contraction without disrupting the electric field potential can be easily identified
since it is an inhibitor of themyosin IIwhich ismainly responsible for the contrac-
tion of cardiomyocytes,while it has noeffect to the ionchannels.Other compound
classes like hERG inhibitors were validated as well and example data will be
shown. They induce typical arrhythmia since hERG ion channels are affected.
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Many drugs, both cardiac and non-cardiac, cause fatal arrhythmias. Current as-
says to evaluate arrhythmia risk based on block of the delayed rectifier Kþ cur-
rent (hERG) and QT interval prolongation are limited by poor specificity. We
hypothesize that physiological, dynamical simulations of drug effects on heart
cells will yield better algorithms to discriminate between arrhythmogenic and
safe drugs. To test this, we model drug action in cardiomyocyte models based
on drug interactionwith 3 cardiac ion channels: hERG, the L-type Ca2þ channel,
and the fast Naþ channel. For 67 distinct drugs, we measure 15 cellular physi-
ological metrics under multiple pacing conditions and in the 3 ventricular cell
types, each in 3 human ventricular cell models. Additionally, we evaluate the
influences of gender and inter-individual variability on risk by conducting sim-
ulations in both female and male models, and in a simulated population of indi-
viduals, respectively. Principal component analysis of these drug effect metrics
reveals distinct behaviors of arrhythmogenic drugs. This segregation of drugs in
principal component space facilitates their classification into arrhythmogenic
and safe categories. Our classification by this method is more sensitive and spe-
cific than the hERG block assay or, to our knowledge, any other published pre-
dictors, with an area under the receiver-operator characteristic of 0.9630.
Furthermore, because it is based on cellular physiologicalmetrics, our algorithm
can predict the arrhythmogenicity of drugswith a range of cardiacmolecular tar-
gets, beyond those of the drugs used to train the algorithm. In conclusion, we
have developed a classification algorithm using dynamical heart cell models,
suitable for cardiac safety assessments early in drug development, that outper-
forms current methods in the discrimination of arrhythmogenic and safe drugs.
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Introduction: Cardiac tissue slices, a pseudo two-dimensional organo-typic
experimental model, are an increasingly popular model to study cardiac
biophysics in-vitro. This preparation benefits from moderate complexity, native
cell-type presence, and locally preserved cell-cell connections. We used optical
mapping of tissue slices to monitor transmembrane potential (Vm) and intracel-
lularCa2þ concentration to study the effects of stretch onactionpotential duration
(APD) and calcium transient (CaT) dynamics with a relatively high spatio-
temporal resolution, to explore mechanisms of stretch-induced arrhythmias.
Methods: Langendorff perfused rabbit hearts were loaded with dyes for Vm
(di-4-ANBDQPQ) and CaT (Rhod-2-AM). Thereafter, 350 mm tissue slices
were vibratome-cut from left and right ventricular free wall in an
epicardium-tangential plane. Slices were attached at their ends to a manual
stretcher and optically mapped using an EMCCD camera with LED excitation
light sources. Slices were field stimulated at 2Hz, and Vm and CaT were
measured before, during (up to 50min) and after application of stretch.
Results: Cardiac tissue slices (n¼9), exposed to stretch (by 4-12%) showed an
initial shortening in both APD and CaT duration (APD80 and APD50 reduced
